https://www.google.com/amp/s/www.bbc.com/news/amp/uk-politics-55422729

Remember that pound sterling now at 2-year high. Their cash and bank balances and amount owing by joint ventures of RM2.5 bil are predominantly in pound sterling.

But everything is still intact. Just delay by a year. FY21 is going to be a very interesting year.

But if you are making comparison to what they promised in the prospectus back in 2017, they are doing it. Just that their plans have been delayed by events beyond their control i.e. Brexit, Covid

Its share price of the Company has been on downtrend due to multiple whammies; possibility of Brexit with no deal, delays in handover of projects, disappointment of financial results, recent merger between UEM – EcoWorld that might affect its shareholding structure, delays of dividend declaration and uncertainties of new projects and prospects going forward. However, it doesn't mean that Ewint is not doing well. It is delaying its fruit harvesting event to a year later.

The best is yet to come. The devil is in the detail. First they secured RM1.4 bil of sales for FY20, with RM448 mil sales for Q4 2020, being their strongest quarterly sales. This affirms the growing demand for properties in UK despite of Brexit. For FY21, projected sales of RM2.2 bil (57% higher than FY20) will be added to future revenue.

And with completion of Yarra One by Q1 21, bulk of portfolio of projects in the pipeline as stated in the IPO back in 2017 have been completed. Next quarter, solely on Yarra One, Ewint will recognise RM728.3 of revenue and approximately RM100 mil of profit. Including other handovers from its existing UK projects it is going to achieve one of the highest profits ever.

Yes, Brexit with deal or not i doesn't matter to the UK. But just that property developers like EWINT waiting for greater certainty on prospects before embarking on new developments

The uptrend is intact. Yesterday selling volume was the same as earlier 3 trading days volumes combined. It was a healthy correction. This is not a trading counter and minimum fair value for this counter is at IPO price of RM1.20.

BeCalm-The Company didn't do any corporate exercises to split its share base since IPO. If u never average your price than the only possible reason it was due to migration to another trading account. During the migration, the cost will automatically set at the date of migration. Tq

the business is in the infancy stage but it is moving fast. Soon the retailers will get excited with this baby

U cannot look much into the write-ups by the Company. You cannot get anything at all. But gauge its prospects by looking into its business model, collaborations, business partnerships and numbers. Numbers tell u a million words. It will tell you the brightness of its story

As the largest retailer in Malaysia with more than 500 k active AEON members, the upliftment of CMCO in most of the states, allowing inter-district and inter-state travel and loosening of CMCO in Klang Valley bode well with the strongest month for AEON. 4 cents dividend per annum, translates in 4% yield and indicators of recovery in process would elevate its share prices to RM1.20 minimum. Look back into the last 5 financial years and you can see that they growing every year.

Nice closing. Bull successfully fended multiple attacks by the bear. Next week, test the resistance level of 53. Multiple catalysts in the pipeline

https://www.google.com/amp/s/amp.theguardian.com/commentisfree/2020/nov/30/boris-johnson-deal-betrayal-brexiters-no-deal

And this time Biden piles Boris Johnson to initiate Brexit with a deal. Is going to be another big catalyst for Ewint

This time its uptrend try to test its immediate resistance of RM0.45. It was a nice long candle yesterday. Announcement of quarterly results in mid of Dec 2020. Hopefully this time around the uptrend is for real

lol, this forum is damn funny especially the comments from the biggest naysayer, roger3210. alright, let's bet on this. I put my bet on upward trajectory on this counter

Cheapest valuation in terms of PE ratio and growth prospects. Flexible developer with mainstream to luxury projects and with sustainable concepts. Lumpy revenue and profits due to accounting standards in UK and AUS but on thing for sure they started to recognise a substantial cash in their joint venture entities. Year end is coming and based on historical trend, it will move upward

https://bdaily.co.uk/articles/2020/11/16/east-london-housing-firm-unveils-masterplan-to-build-more-than-1800-homes

This going to be the same as TopGlove. Market already expected the rubber glove companies to earn big profits. So expect to sell on good news.

Supermax is always a voting machine since the start of the pandemic. Retail investors, fund managers gone frenzy on it. Of course it enjoy a windfall from the pandemic but how long it can sustain? That's for a year to reach the peak of its earnings and thereon, normalise once we got the vaccine. When looking into a stock valuation, look into 2 to 3 years from now or better 5 years. Back to reality, we know that once the pandemic is over the windfall earnings can no longer be sustained.

At present, medical gloves are in great demand, but going forward where is the growth in both ASP and volume post FY21. Is there another leg of growth for the glove industry without any epidemic diseases or pandemic? Slew of companies announced their plans to set up plants to produce rubber gloves, increase their production capacity and lines and many countries announced to ramp-up their glove manufacturing in the next 2-3 years. China and Thailand plans to increase their production of gloves to 100 billion per annum. Will it gradually turn from shortages to gluts in the industry for the next 2 years?

Vaccine or its trials may be delayed or paused but we know that we are going to have a proven commercially viable vaccine as time goes by.

For now, the downside for glove counters is high but upside is limited. So risk is high for the return.

At present, medical gloves are in great demand, but going forward where is the growth in both ASP and volume post FY21. Is there another leg of growth for the glove industry without any epidemic diseases or pandemic? Slew of companies announced their plans to set up plants to produce rubber gloves, increase their production capacity and lines and many countries announced to ramp-up their glove manufacturing in the next 2-3 years. China and Thailand plans to increase their production of gloves to 100 billion per annum. Will it gradually turn from shortages to gluts in the industry for the next 2 years?

Vaccine or its trials may be delayed or paused but we know that we are going to have a proven commercially viable vaccine as time goes by.

For now, the downside for glove counters is high but upside is limited. So risk is high for the return.

At present, medical gloves are in great demand, but going forward where is the growth in both ASP and volume post FY21. Is there another leg of growth for the glove industry without any epidemic diseases or pandemic? Slew of companies announced their plans to set up plants to produce rubber gloves, increase their production capacity and lines and many countries announced to ramp-up their glove manufacturing in the next 2-3 years. China and Thailand plans to increase their production of gloves to 100 billion per annum. Will it gradually turn from shortages to gluts in the industry for the next 2 years?

Vaccine or its trials may be delayed or paused but we know that we are going to have a proven commercially viable vaccine as time goes by.

For now, the downside for glove counters is high but upside is limited. So risk is high for the return.

At present, medical gloves are in great demand, but going forward where is the growth in both ASP and volume post FY21. Is there another leg of growth for the glove industry without any epidemic diseases or pandemic? Slew of companies announced their plans to set up plants to produce rubber gloves, increase their production capacity and lines and many countries announced to ramp-up their glove manufacturing in the next 2-3 years. China and Thailand plans to increase their production of gloves to 100 billion per annum. Will it gradually turn from shortages to gluts in the industry for the next 2 years?

Vaccine or its trials may be delayed or paused but we know that we are going to have a proven commercially viable vaccine as time goes by.

For now, the downside for glove counters is high but upside is limited. So risk is high for the return.

At present, medical gloves are in great demand, but going forward where is the growth in both ASP and volume post FY21. Is there another leg of growth for the glove industry without any epidemic diseases or pandemic? Slew of companies announced their plans to set up plants to produce rubber gloves, increase their production capacity and lines and many countries announced to ramp-up their glove manufacturing in the next 2-3 years. China and Thailand plans to increase their production of gloves to 100 billion per annum. Will it gradually turn from shortages to gluts in the industry for the next 2 years?

Vaccine or its trials may be delayed or paused but we know that we are going to have a proven commercially viable vaccine as time goes by.

For now, the downside for glove counters is high but upside is limited. So risk is high for the return.

At present, medical gloves are in great demand, but going forward where is the growth in both ASP and volume post FY21. Is there another leg of growth for the glove industry without any epidemic diseases or pandemic? Slew of companies announced their plans to set up plants to produce rubber gloves, increase their production capacity and lines and many countries announced to ramp-up their glove manufacturing in the next 2-3 years. China and Thailand plans to increase their production of gloves to 100 billion per annum. Will it gradually turn from shortages to gluts in the industry for the next 2 years?

Vaccine or its trials may be delayed or paused but we know that we are going to have a proven commercially viable vaccine as time goes by.

For now, the downside for glove counters is high but upside is limited. So risk is high for the return.

At present, medical gloves are in great demand, but going forward where is the growth in both ASP and volume post FY21. Is there another leg of growth for the glove industry without any epidemic diseases or pandemic? Slew of companies announced their plans to set up plants to produce rubber gloves, increase their production capacity and lines and many countries announced to ramp-up their glove manufacturing in the next 2-3 years. China and Thailand plans to increase their production of gloves to 100 billion per annum. Will it gradually turn from shortages to gluts in the industry for the next 2 years?

Vaccine or its trials may be delayed or paused but we know that we are going to have a proven commercially viable vaccine as time goes by.

For now, the downside for glove counters is high but upside is limited. So risk is high for the return.

vaccine is coming soon. the demand month-on-month for the gloves is not growing as much as expected

First loss ever. They always in profit for so mny year and this time is huge

AmBank Research noted that the planned capacity increase of 126 billion pieces or 54% by end-2022 “will more than offset” demand increase, and that the recent strides in Covid-19 vaccines will affect ASPs as well.

https://www.theedgemarkets.com/article/ambank-research-says-glovemakers-fully-valued-downgrades-neutral

Danny Wong, chief executive officer at Malaysia-based Areca Capital Sdn., said in an interview that investors will be better off taking some profits in glove stocks over the next few quarters as news on vaccine development has been positive. “Stocks have already rallied a lot,” Wong said.

Danny Wong, chief executive officer at Malaysia-based Areca Capital Sdn., said in an interview that investors will be better off taking some profits in glove stocks over the next few quarters as news on vaccine development has been positive. “Stocks have already rallied a lot,” Wong said.

Danny Wong, chief executive officer at Malaysia-based Areca Capital Sdn., said in an interview that investors will be better off taking some profits in glove stocks over the next few quarters as news on vaccine development has been positive. “Stocks have already rallied a lot,” Wong said.

Danny Wong, chief executive officer at Malaysia-based Areca Capital Sdn., said in an interview that investors will be better off taking some profits in glove stocks over the next few quarters as news on vaccine development has been positive. "Stocks have already rallied a lot, ” Wong said.

https://www.thestar.com.my/business/business-news/2020/08/25/virus-vaccine-could-be-bad-for-red-hot-glove-stocks

Post removed.Why?

Post removed.Why?

https://www.theedgemarkets.com/content/evening-5-glove-bulls-spooked-talk-windfall-tax-1

https://www.theedgemarkets.com/content/evening-5-glove-bulls-spooked-talk-windfall-tax-1

Russia, as it has been said on several occasions, is open to cooperation with any foreign country on the development of the vaccine. Those who are willing to engage with us have expressed their intentions. In Southeast Asia, it is the Philippines and Vietnam. Overall, 20 nations have requested a total of one billion doses of Sputnik V.

https://www.nst.com.my/opinion/letters/2020/08/617058/russia-has-sent-covid-19-vaccine-info-malaysia

https://www.google.com/amp/s/m.timesofindia.com/life-style/health-fitness/health-news/coronavirus-vaccine-india-3-covid-vaccines-in-trial-phase-india-ready-to-mass-produce-says-pm-modi/amp_etphotostory/77561111.cms

https://www.google.com/amp/s/news.cgtn.com/news/2020-08-15/China-Sinopharm-s-COVID-19-vaccine-candidate-seems-to-work-Journal-SYTru0Oasw/share_amp.html

National pride is defining the race for a Covid 19 vaccine. Companies in US, China racing to complete the trials after Russia declared victory in global vaccine race. More to come. Be careful as demand and high average selling price is not sustainable.

National pride is defining the race for a Covid 19 vaccine. Companies in US, China racing to complete the trials after Russia declared victory in global vaccine race. More to come. Be careful as demand and high average selling price is not sustainable.

Fall from grace soon. Stock market is all about sentiments. 2nd half result of Supermax should be good because of the windfall from this pandemic. But development of vacccine from all countries already at final stage and most of them already at final stage of clinical trials. That's imminent

OCK couldn’t match its profit with cashflow and its dilution with issuance of new share capital to fund for expansion activities means that shareholders own less of the company than the did before (unless they bought more shares). For that reasons, despite showing growing earnings but the earnings apparently are lower quality

And why their receivables keep growing every year. That's because they provide financing to their customers but this has put a burden on cash inflow of the Group. Hence, they need to incur more debt and raise more funds to stimulate growth. As for IPO listing, it would not be materialised at least a year or two